EUVIMEDEUVIMED entdecken
Crossref

Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy

Yi Xu, ShuangJie Li, Yingping Gu, Meng Yang, Sisi Li, Ling Ye, Songxu Peng iD

Journal of the Pediatric Infectious Diseases Society · 2025

DOI: 10.1093/jpids/piaf083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2025. Verfasst von Yi Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha 410078, China. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Hepatitis B Surface Antigens, Immune Tolerance. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are no established recommendations for the most suitable treatment of children with immune-tolerant chronic hepatitis B (CHB). To evaluate the clinical outcome of combination therapy among treatment-naïve children with immune-tolerant CHB, we conducted this study.

Methods

We retrospectively identified pediatric patients who were diagnosed with immune-tolerant CHB and who received combination therapy with interferon-alpha or peginterferon-alpha-2a plus entecavir at Hunan Children’s Hospital between August 2014 and April 2023. A total of 106 patients were ultimately enrolled in the study. Complete clinical data were collected for all the enrolled patients. The associations between baseline characteristics and HBsAg loss were assessed using Cox proportional hazards regression. Restricted cubic spline (RCS) plots were constructed to portray the association between HBsAg loss and patient age.

Results

After a median follow-up of 87 weeks, 23.5% (25/106) of the participants achieved sustained HBsAg loss, with a cumulative incidence of 44.9%. Proportional hazard regression indicated a significant association between achieving HBsAg loss and age, HBsAg level, and HBsAb level at baseline. The RCS plots suggested that, for pediatric patients, initiating antiviral therapy for immune-tolerant CHB might be most beneficial when they are less than 5 years old. Seventy-five (70.8%) patients experienced adverse events (AEs) following interferon therapy, with no severe AEs leading to treatment discontinuation.

Conclusions

The combination therapy led to favorable clinical outcomes for children with immune-tolerant CHB. Moreover, young age and low HBsAg and high HBsAb levels at baseline are predictors of a clinical cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicHepatitis B Surface AntigensImmune ToleranceHumansMaleFemaleChildRetrospective StudiesChild, PreschoolInterferon-alphaAdolescentDrug Therapy, CombinationIncidenceRecombinant ProteinsPolyethylene GlycolsGuanineTreatment OutcomeInfant

Stichwörter der Autor:innen

antiviral therapychildrenchronic HBV infectionimmune tolerancepredictors

Substanzen

Antiviral AgentsHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aRecombinant ProteinsentecavirPolyethylene GlycolsGuanine

Autor:innen und Institutionen

  • Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha 410078, China.
  • Department of Hepatopathy Center, Hunan Children's Hospital, Changsha 410007, China.

ORCID-Profile: Songxu Peng

Förderung

  • Natural Science Foundation of Hunan Province
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Y., Li, S., Gu, Y., Yang, M., Li, S., Ye, L., & Peng, S. (2025). Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaf083

Vancouver

Xu Y, Li S, Gu Y, Yang M, Li S, Ye L, et al. Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy. Journal of the Pediatric Infectious Diseases Society. 2025. doi:10.1093/jpids/piaf083

BibTeX
@article{Xu2025,
  author = {Xu, Yi and Li, ShuangJie and Gu, Yingping and Yang, Meng and Li, Sisi and Ye, Ling and Peng, Songxu},
  title = {Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2025},
  doi = {10.1093/jpids/piaf083}
}
Kostenlos starten →